Posted On: 12/20/2014 9:34:52 AM
Post# of 30066
Internation Infusion
http://globenewswire.com/news-release/2014/12...r0hjC.dpuf
____________________________________________________________________________
http://internationalinfusion.com/contact/
Quote:
San Francisco and Geneva, Dec. 19, 2014 (Globe Newswire) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has entered into definitive agreements to raise an additional $2.0 million under its previously announced transaction to issue shares of Series E Preferred Stock (the Series E), bringing the total capital raised to $5.0 million. The 2nd closing was led by International Infusion.
http://globenewswire.com/news-release/2014/12...r0hjC.dpuf
____________________________________________________________________________
Quote:
International Infusion
Gerald E. Commissiong - Strategic Consultant
Gerald is currently President & CEO of Amarantus BioSciences and a member of the Board of Directors. He co-founded Amarantus with John Commissiong, PhD in 2008. From the inception of the Company, Gerald attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and executive talent to Amarantus to allow for the further development of the technologies. Gerald works with International Infusion as an advisor bringing expertise in Public and Private Finance.
Gerald received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University. Gerald also played professional football for the Calgary Stampeders of the Canadian Football League.
http://internationalinfusion.com/contact/
(0)
(0)
